| 小细胞肺癌的二线化疗及研究进展 |
| |
| 引用本文： | 李兰芳,王华庆.小细胞肺癌的二线化疗及研究进展[J].肿瘤研究与临床,2006,18(6):424-426. |
| |
| 作者姓名： | 李兰芳 王华庆 |
| |
| 作者单位： | 300060,天津医科大学附属肿瘤医院内一科 |
| |
| 摘 要： | 小细胞肺癌（SCLC）恶性度较高，早期即可发生血行转移，但对放化疗敏感，故SCLC治疗应以全身化疗为主，联合放疗和手术为主要治疗手段。尽管SCLC化疗的有效率较高，但对于广泛期SCLC患者，从化疗耐药开始至患者死亡的中位时间仍不满意。对于局限期 SCLC患者在诱导放化疗后仍有75 % ~ 80 %出现复发，故二线治疗是治疗SCLC的重点。
|
| 关 键 词： | 小细胞肺癌 二线化疗 |
| 文章编号： | 1006-9801（2006）06-0424-03 |
| 收稿时间： | 2005-08-03 |
| 修稿时间： | 2006-04-20 |
The study progress and second-line chemotherapy of small cell lung cancer |
| |
| LI Lan-fang,WANG Hua-qing.The study progress and second-line chemotherapy of small cell lung cancer[J].Cancer Research and Clinic,2006,18(6):424-426. |
| |
| Authors: | LI Lan-fang WANG Hua-qing |
| |
| Institution: | 1st Department of Internal Medicine, Affiliated Hospital to Tianjin Medical University, Tianjin 300060, China |
| |
| Abstract: | Small cell lung cancer(SCLC) is an chemosensitive and radiosensitive malignant tumor which can appear hematogenous metastasis in early stage. The treatment of SCLC is based on chemotherapy and combined with radiotherapy and operation. In spite of the high response rate, the median time from drug-resistance to death of extensive SCLC is still disappointed. As to limited SCLC, there are still 75 % ~ 80 % patients relapse after inductive chemotherapy and radiotherapy. All in all, the second-line therapy is very important in SCLC patients. |
| |
| Keywords: | Second-line chemotherapy Small cell lung cancer |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《肿瘤研究与临床》浏览原始摘要信息 |
| 点击此处可从《肿瘤研究与临床》下载免费的PDF全文 |
